FulvestrantA Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women

被引：0
|
作者：
Jamie D. Croxtall
Kate McKeage
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Tamoxifen; Postmenopausal Woman; Anastrozole; Exemestane; Fulvestrant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fulvestrant (Faslodex®) is an intramuscularly administered steroidal estrogen receptor antagonist that is devoid of any known estrogen agonist effects. It is indicated as second-line therapy for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer who have progressed following prior endocrine therapy.
引用
收藏
页码：363 / 380
页数：17
相关论文
共 50 条
  • [31] Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
    Anishka D’Souza
    Darcy Spicer
    Janice Lu
    Journal of Hematology & Oncology, 11
  • [32] Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
    D'Souza, Anishka
    Spicer, Darcy
    Lu, Janice
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [33] POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER: BALANCING BENEFIT AND TOXICITY FROM AROMATASE INHIBITORS
    Ingle, J.
    BREAST, 2013, 22 : S19 - S19
  • [34] The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer
    Pennery, Emma
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2008, 12 (03) : 233 - 243
  • [35] FULVESTRANT ('FASLODEX'): A NEW OPTION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
    Kleeberg, Ulrich R.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3537 - 3537
  • [36] Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer
    Bundred, N
    CANCER INVESTIGATION, 2005, 23 (02) : 173 - 181
  • [37] Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors
    Ingle, James N.
    BREAST, 2013, 22 : S180 - S183
  • [38] Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer
    Esteva, Francisco J.
    Moulder, Stacy L.
    Gonzalez-Angulo, Ana M.
    Ensor, Joe
    Murray, James L.
    Green, Marjorie C.
    Koenig, Kimberly B.
    Lee, Mong-Hong
    Hortobagyi, Gabriel N.
    Yeung, Sai-Ching
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 63 - 72
  • [39] FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
    Shah, Anand
    Bloomquist, Erik
    Tang, Shenghui
    Fu, Wentao
    Bi, Youwei
    Liu, Qi
    Yu, Jingyu
    Zhao, Ping
    Palmby, Todd R.
    Goldberg, Kirsten B.
    Chang, C. J. George
    Patel, Paresma
    Alebachew, Elleni
    Tilley, Amy
    Pierce, William F.
    Ibrahim, Amna
    Blumenthal, Gideon M.
    Sridhara, Rajeshwari
    Beaver, Julia A.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2018, 24 (13) : 2999 - 3004
  • [40] Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
    Cristofanilli, Massimo
    Valero, Vicente
    Mangalik, Aroop
    Royce, Melanie
    Rabinowitz, Ian
    Arena, Francis P.
    Kroener, Joan F.
    Curcio, Elizabeth
    Watkins, Claire
    Bacus, Sarah
    Cora, Elsa M.
    Anderson, Elizabeth
    Magill, Patrick J.
    CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1904 - 1914
12345